Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Abstract

Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other manifestations of systemic sclerosis. The adverse-event profile of nintedanib observed in this trial was similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse events, including diarrhea, were more common with nintedanib than with placebo. (Funded by Boehringer Ingelheim; SENSCIS ClinicalTrials.gov number, NCT02597933.).

Keywords

MeSH Terms

Affiliated Institutions

• Cleveland Clinic US
• University of Colorado Denver US
• National Institute for Health Research GB
• University of Tübingen DE
• Boehringer Ingelheim (China) HK
• Nippon Medical School JP
• University of Washington US
• Boehringer Ingelheim (France) FR
• University Hospital of Zurich CH
• Seattle University US
• Boehringer Ingelheim (South Korea) KR
• Royal Brompton Hospital GB

Related Publications